BTK and mantle cell lymphoma: MCL cells can develop de novo resistance through a dynamic interplay between lymphoma cells and their TME, mediated by the triggering of BTK, ERK, and AKT activation and enhanced survival through the synthesis of several chemokines and cytokines, including BAFF.